Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
yinhua ganmao keli
- Development stage
- Unknown
- Lead developer
- Guizhou Shengshi Longfang Pharmaceutical
- Administration
- Oral
01
Overview
Yinhua Ganmao Keli is a traditional Chinese medicine (TCM) herbal formulation developed and manufactured by Guizhou Shengshi Longfang Pharmaceutical. It is produced as oral granules that are dissolved in water before administration. The drug is indicated for the symptomatic relief of the common cold and upper respiratory tract infections. The formulation is primarily based on honeysuckle (Yinhua), which is traditionally used in TCM for its antipyretic and anti-inflammatory properties. It has received marketing approval from the National Medical Products Administration (NMPA) in China.
- Brand names
- 银花感冒颗粒Yinhua Ganmao Keli
- Other names
- Honeysuckle Cold GranulesCold Granules
Beyond the preview
Go deeper on yinhua ganmao keli.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on yinhua ganmao keli.